Patents by Inventor Piero Anversa

Piero Anversa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200054684
    Abstract: Embodiments of the invention relate to human, non-mesenchymal c-kit positive lung stem cells negative for the CD44, CD73 and CD105 markers of the mesenchymal stromal cell lineage (non-mhLSCs) and their therapeutic use in the treatment and/or prevention of lung diseases or disorders. Provided herein are compositions comprising non-mhLSCs and methods of preparing and using non-mhLSCs for the treatment and/or prevention of lung diseases or disorders.
    Type: Application
    Filed: November 2, 2017
    Publication date: February 20, 2020
    Applicant: AAL SCIENTIFICS, INC.
    Inventors: Piero ANVERSA, Annarosa LERI
  • Publication number: 20190365822
    Abstract: Disclosed herein are compositions comprising cardiac progenitor cells that express exogenous p53 protein. Such compositions are useful for treating cardiac diseases or disorders. Also disclosed herein are methods of producing cardiac progenitor cells that express exogenous p53.
    Type: Application
    Filed: February 1, 2018
    Publication date: December 5, 2019
    Applicant: AAL SCIENTIFICS, INC.
    Inventors: Piero ANVERSA, Annarosa LERI
  • Publication number: 20190343888
    Abstract: Disclosed herein are compositions comprising myogenic bone marrow cells that are c-kit positive. Such compositions are useful for treating cardiac diseases or disorders. Also disclosed herein are methods of producing myogenic bone marrow cells are c-kit positive. Further disclosed are cardiopoietic genes having enhanced expression in c-kit positive myogenic bone marrow cells.
    Type: Application
    Filed: February 1, 2018
    Publication date: November 14, 2019
    Applicant: AAL SCIENTIFICS, INC.
    Inventors: Piero ANVERSA, Annarosa LERI
  • Publication number: 20190030083
    Abstract: Embodiments of the invention relate to stem cells and their therapeutic use in the treatment and/or prevention of neurological diseases or disorders. Provided herein are compositions comprising c-kit positive neural stem cells and methods of preparing and using c-kit positive neural stem cells for the treatment and/or prevention of neurological diseases or disorders.
    Type: Application
    Filed: March 6, 2017
    Publication date: January 31, 2019
    Inventor: Piero Anversa
  • Publication number: 20180055889
    Abstract: Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy.
    Type: Application
    Filed: November 6, 2017
    Publication date: March 1, 2018
    Inventors: Piero Anversa, Annarosa Leri
  • Patent number: 9808489
    Abstract: Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 7, 2017
    Assignee: AAL Scientifics, Inc.
    Inventors: Piero Anversa, Annarosa Leri
  • Publication number: 20170258853
    Abstract: The disclosure relates to stem cells and their therapeutic use in the treatment and/or prevention of pancreatic diseases or disorders. Provided herein are compositions comprising c-kit positive pancreatic stem cells and methods of preparing and using c-kit positive pancreatic stem cells for the treatment and/or prevention of pancreatic diseases or disorders.
    Type: Application
    Filed: March 7, 2017
    Publication date: September 14, 2017
    Inventor: Piero Anversa
  • Publication number: 20170165301
    Abstract: Embodiments of the invention relate to human stem cells and their therapeutic use in the treatment and/or prevention of lung diseases. Provided herein are compositions comprising c-kit positive human lung stem cells and methods of preparing and using c-kit positive human lung stem cells for the treatment and/or prevention of lung diseases.
    Type: Application
    Filed: November 23, 2016
    Publication date: June 15, 2017
    Applicant: AAL Scientifics, Inc.
    Inventors: Piero ANVERSA, Annarosa LERI
  • Patent number: 9644238
    Abstract: The invention describes the isolation and methods of use of a non-senescent pool of adult cardiac stem cells. In particular, a subset of adult cardiac stem cells with superior regenerative capacity is disclosed. Such cells were found to have immortal DNA. Compositions comprising the non-senescent stem cells are also described. In addition, the present invention provides methods for repairing aged myocardium or damaged myocardium using the isolated non-senescent adult cardiac stem cells.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: May 9, 2017
    Assignee: AUTOLOGOUS REGENERATION, LLC
    Inventors: Piero Anversa, Annarosa Leri, Jan Kajstura
  • Patent number: 9534204
    Abstract: Embodiments of the invention relate to human stem cells and their therapeutic use in the treatment and/or prevention of lung diseases. Provided herein are compositions comprising c-kit positive human lung stem cells and methods of preparing and using c-kit positive human lung stem cells for the treatment and/or prevention of lung diseases.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: January 3, 2017
    Assignee: AAL Scientifics, Inc.
    Inventors: Piero Anversa, Annarosa Leri
  • Publication number: 20160220614
    Abstract: Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 4, 2016
    Inventors: Piero Anversa, Jan Kajstura, Annarosa Leri
  • Patent number: 8663627
    Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration cytokines are disclosed and claimed. Methods and compositions for the development of large arteries and vessels are also disclosed and claimed. The present application also discloses and claims methods and media for the growth, expansion, and activation of human cardiac stem cells.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: March 4, 2014
    Assignee: New York Medical College
    Inventor: Piero Anversa
  • Publication number: 20140051077
    Abstract: The invention describes the isolation and methods of use of a non-senescent pool of adult cardiac stem cells. In particular, a subset of adult cardiac stem cells with superior regenerative capacity is disclosed. Such cells were found to have immortal DNA. Compositions comprising the non-senescent stem cells are also described. In addition, the present invention provides methods for repairing aged myocardium or damaged myocardium using the isolated non-senescent adult cardiac stem cells.
    Type: Application
    Filed: August 19, 2013
    Publication date: February 20, 2014
    Applicant: Autologous, LLC
    Inventors: Piero ANVERSA, Annarosa Leri, Jan Kajstura
  • Patent number: 8623351
    Abstract: The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: January 7, 2014
    Assignee: New York Medical College
    Inventors: Piero Anversa, Annarosa Leri, Jan Kajstura
  • Patent number: 8617889
    Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are disclosed and claimed. In addition, methods, compositions, and kits for forming coronary vasculature including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are described. In particular, administration of variants of hepatocyte growth factor, such as NK1, 1K1, and HP11, are useful for the repair and/or regeneration of damaged myocardium or formation of coronary vasculature. Methods of activating cardiac stem cells in vitro are also disclosed.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: December 31, 2013
    Assignee: New York Medical College
    Inventor: Piero Anversa
  • Publication number: 20130288962
    Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration cytokines are disclosed and claimed. Methods and compositions for the development of large arteries and vessels are also disclosed and claimed. The present application also discloses and claims methods and media for the growth, expansion, and activation of human cardiac stem cells.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 31, 2013
    Inventor: Piero Anversa
  • Patent number: 8551475
    Abstract: The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively, bone marrow progenitor cells (BMPCs) isolated from the recipient may also be used.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: October 8, 2013
    Assignee: New York Medical College
    Inventors: Piero Anversa, Annarosa Leri, Jan Kajstura
  • Publication number: 20130216508
    Abstract: Embodiments of the invention relate to human stem cells and their therapeutic use in the treatment and/or prevention of lung diseases. Provided herein are compositions comprising c-kit positive human lung stem cells and methods of preparing and using c-kit positive human lung stem cells for the treatment and/or prevention of lung diseases.
    Type: Application
    Filed: October 5, 2011
    Publication date: August 22, 2013
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Piero Anversa, Mark Perrella, Annarosa Leri, Jan Kajstura
  • Patent number: 8512696
    Abstract: The invention describes the isolation and methods of use of a non-senescent pool of adult cardiac stem cells. In particular, a subset of adult cardiac stem cells with superior regenerative capacity is disclosed. Such cells were found to have immortal DNA. Compositions comprising the non-senescent stem cells are also described. In addition, the present invention provides methods for repairing aged myocardium or damaged myocardium using the isolated non-senescent adult cardiac stem cells.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: August 20, 2013
    Assignee: Autologous, LLC
    Inventors: Piero Anversa, Annarosa Leri, Jan Kajstura
  • Patent number: 8497252
    Abstract: The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: July 30, 2013
    Assignee: New York Medical College
    Inventors: Toru Hosoda, Piero Anversa, Annarosa Leri, Jan Kajstura